Denosumab superior to Zometa for bone metastases in CaP

[Guest guest]

Amgen has announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa* (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. Denosumab demonstrated superiority over Zometa for both delaying the time to the first on-study skeletal related event (SRE) (fracture, radiation to bone, surgery to bone or spinal cord compression) (hazard ratio 0.82, 95 percent CI: 0.71, 0.95), and reducing the rate of multiple SREs (hazard ratio 0.82, 95 percent CI: 0.71, 0.94). Both results were statistically significant....

Click on the below link for the full story:<http://www.news-medical.net/news/20100209/Denosumab-exhibits-superiority-over-Zometa-in-treatment-of-prostate-cancer-men-with-bone-metastases.aspx>/

div>